An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries

BACKGROUND: The Canadian government has committed to developing a national strategy for drugs for rare diseases starting in 2022. Considering this announcement, we conducted a comparative analysis to examine patient access to therapies for rare disease in Canada relative to Europe and the U.S. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Leanne Marie, Chambers, Alexandra, Mechichi, Emine, Wong-Rieger, Durhane, Campbell, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895096/
https://www.ncbi.nlm.nih.gov/pubmed/35246200
http://dx.doi.org/10.1186/s13023-022-02260-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895096/
https://www.ncbi.nlm.nih.gov/pubmed/35246200
http://dx.doi.org/10.1186/s13023-022-02260-6

Ejemplares similares